Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 13.86% is in line with its 5-year average of 14.86%, near the low end of its 5-year range (11.56%–19.97%).
10.53% above its 12-month average of 12.54%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
13.86%
RETURN ON ASSETS (ROA) AVG TTM
12.54%
RETURN ON ASSETS (ROA) AVG 3Y
14.20%
RETURN ON ASSETS (ROA) AVG 5Y
14.86%
RETURN ON ASSETS (ROA) AVG 10Y
12.23%
RETURN ON ASSETS (ROA) AVG 15Y
10.28%
RETURN ON ASSETS (ROA) AVG 20Y
9.35%
CURRENT VS TTM AVG
+10.53%
CURRENT VS 3Y AVG
-2.36%
CURRENT VS 5Y AVG
-6.71%
CURRENT VS 10Y AVG
+13.32%
CURRENT VS 15Y AVG
+34.82%
CURRENT VS 20Y AVG
+48.23%
SECTOR MEDIAN · HEALTHCARE
4.94%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+180.57%
vs the sector median at left
West Pharmaceutical Services, Inc.
Market Cap
$24.73B
Return on Assets (ROA)
13.86%
TTM Avg
12.54%
3Y Avg
14.20%
5Y Avg
14.86%
Market Cap
$24.54B
Return on Assets (ROA)
20.48%
TTM Avg
9.54%
3Y Avg
8.43%
5Y Avg
7.44%
Market Cap
$24.03B
Return on Assets (ROA)
-28.75%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
Market Cap
$23.31B
Return on Assets (ROA)
-6.03%
TTM Avg
-3.96%
3Y Avg
9.16%
5Y Avg
17.06%
Market Cap
$26.21B
Return on Assets (ROA)
6.27%
TTM Avg
5.75%
3Y Avg
6.24%
5Y Avg
8.30%
Market Cap
$26.44B
Return on Assets (ROA)
5.41%
TTM Avg
4.41%
3Y Avg
4.42%
5Y Avg
6.18%
Market Cap
$21.88B
Return on Assets (ROA)
18.16%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
Market Cap
$29.04B
Return on Assets (ROA)
24.67%
TTM Avg
25.02%
3Y Avg
24.63%
5Y Avg
23.85%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.73B | 13.86% | 12.54% | 14.20% | 14.86% |
| Incyte Corporation (INCY)vs › | $24.54B | 20.48% | 9.54% | 8.43% | 7.44% |
| Moderna, Inc. (MRNA)vs › | $24.03B | -28.75% | -24.02% | -10.32% | -0.33% |
| BioNTech SE (BNTX)vs › | $23.31B | -6.03% | -3.96% | 9.16% | 17.06% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.21B | 6.27% | 5.75% | 6.24% | 8.30% |
| STERIS plc (STE)vs › | $23.22B | 5.64% | 6.68% | 4.44% | 4.33% |
| Labcorp Holdings Inc. (LH)vs › | $26.44B | 5.41% | 4.41% | 4.42% | 6.18% |
| United Therapeutics Corporation (UTHR)vs › | $21.88B | 18.16% | 16.59% | 14.73% | 13.22% |
| Mettler-Toledo International Inc. (MTD)vs › | $29.04B | 24.67% | 25.02% | 24.63% | 23.85% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.60B | 14.54% | -0.12% | -10.91% | -15.37% |
ROA
13.9%
ROE
18.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 11.56% |
| 2024-12-31 | 13.52% |
| 2023-12-31 | 15.50% |
| 2022-12-31 | 16.20% |
| 2021-12-31 | 19.97% |
| 2020-12-31 | 12.39% |
| 2019-12-31 | 10.32% |
| 2018-12-31 | 12.99% |
| 2017-12-31 | 8.09% |
| 2016-12-31 | 8.36% |
| 2015-12-31 | 5.64% |
| 2014-12-31 | 7.61% |
| 2013-12-31 | 6.72% |
| 2012-12-31 | 5.16% |
| 2011-12-31 | 5.40% |
| 2010-12-31 | 5.05% |
| 2009-12-31 | 5.71% |
| 2008-12-31 | 7.36% |
| 2007-12-31 | 5.96% |
| 2006-12-31 | 7.31% |
| 2005-12-31 | 5.54% |
| 2004-12-31 | 2.95% |
| 2003-12-31 | 5.12% |
| 2002-12-31 | 3.43% |
| 2001-12-31 | -1.02% |
| 2000-12-31 | 0.29% |
| 1999-12-31 | 7.01% |
| 1998-12-31 | 1.33% |
| 1997-12-31 | 9.29% |
| 1996-12-31 | 3.44% |
